1. Home
  2. TENX vs CAF Comparison

TENX vs CAF Comparison

Compare TENX & CAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$13.64

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Logo Morgan Stanley China A Share Fund Inc.

CAF

Morgan Stanley China A Share Fund Inc.

HOLD

Current Price

$20.10

Market Cap

333.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
CAF
Founded
1967
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
317.8M
333.7M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
TENX
CAF
Price
$13.64
$20.10
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
898.1K
23.5K
Earning Date
05-15-2026
01-01-0001
Dividend Yield
N/A
1.02%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.67
$13.67
52 Week High
$18.38
$20.57

Technical Indicators

Market Signals
Indicator
TENX
CAF
Relative Strength Index (RSI) 67.28 58.65
Support Level $13.16 $19.03
Resistance Level $14.15 $20.41
Average True Range (ATR) 0.72 0.33
MACD 0.30 0.02
Stochastic Oscillator 99.40 82.46

Price Performance

Historical Comparison
TENX
CAF

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About CAF Morgan Stanley China A Share Fund Inc.

Morgan Stanley China A Share Fund Inc is the United States based non-diversified, closed-end management investment company. Its investment objective is to seek capital growth by investing a majority of its assets in A-shares of Chinese companies listed on the Shanghai and Shenzhen Stock Exchanges. Its portfolio of investments consists of investment in different sectors such as the aerospace and defense, banks, automobiles, household durables, media, pharmaceuticals, software and other sectors.

Share on Social Networks: